Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00750 (PLA)
 16,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Tissue-type plasminogen activator (rt-PA), a gene-technologically manufactured fibrinolytic compound, has been employed successfully for treatment of cardial and peripheral arterial vascular occlusions. The advantage of this compound is its lytic effect. It selectively displays its effect in therapeutic dosage on fresh thrombuses, showing only minimal influence on physiological clotting as such. Two patients with stop of the retinal arterial bloodflow in videofluorescence angiography were treated with short term lysis with 100 mg rt-PA, the onset of therapy was 7 and 6.5 hours after loss of vision. Already during the infusion of the compound reperfusion was achieved. Inspite of the relatively late onset of treatment, the visual fields of both patients improved. We assume lytic therapy with rt-PA to be an effective therapy for patients with retinal arterial occlusion, if applied within the first eight hours after acute loss of vision. The number of patients who could potentially benefit from this therapy is limited considering the high rate of spontaneous reperfusion before the first eye exam in 84% of the cases and considering the manifold contraindications for this therapy: 35% of the patients above 70 years of age, 56% of the patients with arterial hypertension (RR 160/100 and above) as well as 10% of the patients treated with Coumarine-derivatives should not undergo lysis. Only 43% of the patients with occlusion of central retinal artery and 21% of the patients with occlusion of retinal branch arteries received the first eye exam within the first 8 hours after the occlusion.
 ...
PMID:[Thrombolytic treatment of retinal arterial occlusions with plasminogen activator]. 190 33

A study was undertaken to investigate the possible interaction between pentoxifylline and coumarin. Ten patients on a previously stable anticoagulant treatment were investigated twice prior to, then 13 and 27 days after initiation of treatment with 1600 mg pentoxifylline daily. Coumarin therapy was continued in unaltered dosage. Parameters recorded were: bleeding time, platelet count, platelet adhesivity, spontaneous and collagen-induced platelet aggregation, activated partial thromboplastin time, prothrombin time, prothrombin-proconvertin activity, plasminogen activator and fibrin(ogen) degradation products. Platelet aggregation studies revealed a slightly higher sensitivity to collagen in 2 patients compared to pre-treatment values and in 1 patient the tendency to spontaneous aggregation was slightly increased after treatment. No other single test result changed significantly from premedication baseline values.
 ...
PMID:Pentoxifylline does not interfere with stable coumarin anticoagulant therapy: a clinical study. 376 53

The aim of our study was to develop a novel method for the preparation of polymeric core-shell nanoparticles loaded with various actives for biomedical applications. Poly(caprolactone) (PCL), poly(lactic acid) (PLA) and poly(lactide-co-glycolide) (PLGA) nanoparticles were prepared using the spontaneous emulsification solvent evaporation (SESE) method. The model active substance, Coumarin-6, was encapsulated into formed polymeric nanoparticles, then they were modified/functionalized by multilayer shells' formation. Three types of multilayered shells were formed: two types of polyelectrolyte shell composed of biocompatible and biodegradable polyelectrolytes poly-L-lysine hydrobromide (PLL), fluorescently-labeled poly-L-lysine (PLL-ROD), poly-L-glutamic acid sodium salt (PGA) and pegylated-PGA (PGA-g-PEG), and hybrid shell composed of PLL, PGA, and SPIONs (superparamagnetic iron oxide nanoparticles) were used. Multilayer shells were constructed by the saturation technique of the layer-by-layer (LbL) method. Properties of our polymeric core-shell nanoparticle were optimized for bioimaging, passive and magnetic targeting.
 ...
PMID:Polymeric Core-Shell Nanoparticles Prepared by Spontaneous Emulsification Solvent Evaporation and Functionalized by the Layer-by-Layer Method. 3216 94

Phagocytic clearance and inefficient targeting are two major concerns for nanomedicines in cancer therapy. In this study, cell membrane inspired multifunctional copolymers (PMNCFs) were synthesized by a combination of cell membrane stealthy hydrophilic phosphorylcholine (PC), hydrophobic cholesterol (Chol) and tumor targeting folic acid (FA) functionalities on the different side chain ends. PMNCF micelles were prepared in aqueous solution to form a cell membrane mimetic structure with linked folic acid ligands as the protruding antennae on the surface of the micelles. Coumarin-6 loaded PMNCF micelles indicated that the mouse peritoneal macrophage cell uptake efficiency was suppressed to 1/10 compared with that of PLA nanoparticles. Doxorubicin loaded micelle measurements demonstrated that up to 30% of the drug could be obtained forming a stable formulation under both storage and physiological conditions. Tumor cell uptake and toxicity studies revealed that FA-decorated PMNCF micelles could increase MADB-106 cell uptake by 4-fold, and DOX loaded PMNCF micelles could kill tumor cells more efficiently than the same amount of free DOX. These exciting results confirmed the great potential of the stable, stealthy and tumor cell targeting PMNCF micelles for developing advanced long circulation and target-selective drug delivery nanoparticles.
 ...
PMID:Anti-phagocytosis and tumor cell targeting micelles prepared from multifunctional cell membrane mimetic polymers. 3226 70